Association Between Patient-Reported Outcomes and Treatment Failure in Juvenile Idiopathic Arthritis

Alysha Taxter1, Brittany C Donaldson2, Joseph Rigdon2

  • 1Nationwide Children's Hospital, Columbus, Ohio.

ACR Open Rheumatology
|June 18, 2022
PubMed

Insights

Higher energy and longer symptom duration before diagnosis in children with juvenile idiopathic arthritis (JIA) were linked to better treatment outcomes. This suggests patient-reported data can improve JIA therapy effectiveness.

Area of Science:

  • Pediatric Rheumatology
  • Clinical Outcomes Research
  • Patient-Reported Outcomes

Background:

  • Juvenile idiopathic arthritis (JIA) diagnosis is often preceded by months of symptoms.
  • Understanding factors influencing treatment response in JIA is crucial for improving patient care.

Purpose of the Study:

  • To determine if baseline patient-reported outcomes (PROs) predict changes in JIA pharmacotherapy.
  • To investigate the association between pre-diagnosis symptom duration and JIA disease activity over time.

Main Methods:

  • Retrospective cohort study of 58 children diagnosed with JIA.
  • Collected data on symptom duration, pain, energy, sleep, anxiety, depression, and disease activity.
  • Used Cox proportional hazards and mixed effects linear regression to analyze medication failure and disease activity.

Main Results:

  • Nearly half of patients experienced initial medication failure within 9 months.
  • Longer symptom duration and higher energy levels at diagnosis were protective against medication failure.
  • Symptom duration showed a transient association with higher disease activity in the early post-diagnosis period.

Conclusions:

  • Increased energy and prolonged symptom duration prior to diagnosis appear to protect against initial treatment failure in JIA.
  • Incorporating patient-reported data into treatment decisions may enhance therapeutic success in JIA management.
Abstract

Related Concept Videos

Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
3.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
199
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
229
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
370
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.6K